Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma

Annexin V apoptosis detection kit ; 62700 ;

Cell Discov. 2024 Jan 9;10(1):5. doi: 10.1038/s41421-023-00625-0.

Wen Lei ^# 1 2, Ai Zhao ^# 3 4, Hui Liu ^# 1 2, Chunmei Yang ², Cheng Wei ³, Shanshan Guo ¹, Zhilu Chen ⁵, Qunyi Guo ⁶, Linjie Li ⁷, Mingzhe Zhao ⁸, Gongqiang Wu ⁹, Guifang Ouyang ¹⁰, Ming Liu ¹¹, Jinyi Zhang ¹², Jimin Gao ^13 14, Wenbin Qian ^15 16

Affiliations expand

• PMID: 38191529
• PMCID: PMC10774422
• DOI: 10.1038/s41421-023-00625-0

Abstract

Although CD19-specific chimeric antigen receptor (CAR) T cells are curative for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), disease relapse with tumor antigen-positive remains a challenge. Cytokine/chemokine-expressing CAR-T cells could overcome a suppressive milieu, but the clinical safety and efficacy of this CAR-T therapy remain unclear. Here we report the preclinical development of CD19-specific CAR-T cells capable of expressing interleukin (IL)-7 and chemokine (C-C motif) ligand (CCL)-19 upon CD19 engagement (referred to as 7 × 19 CAR-T cells) and results from a phase 1 and expansion phase trial of 7 × 19 CAR-T cell therapy in patients with R/R LBCL (NCT03258047). In dose-escalation phase, there were no dose-limiting toxicities observed. 39 patients with R/R LBCL received 7 × 19 CAR-T with doses ranged from 0.5 × 10⁶-4.0 × 10⁶ cells per kg body weight. Grade 3 cytokine release syndrome occurred in 5 (12.8%) patients and ≥ grade 3 neurotoxicity in 4 (10.3%) patients. The overall response rate at 3 months post-single infusion was 79.5% (complete remission, 56.4%; partial response, 23.1%). With a median follow-up of 32 months, the median progression-free survival was 13 months, and median overall survival was not reached, with an estimated rate of 53.8% (95% CI, 40.3% to 72.0%) at two years. Together, these long-term follow-up data from the multicenter clinical study suggest that 7 × 19 CAR-T cells can induce durable responses with a median overall survival of greater than 2 years, and have a manageable safety profile in patients with R/R LBCL.